Literature DB >> 12507909

Development of colitis in signal transducers and activators of transcription 6-deficient T-cell receptor alpha-deficient mice: a potential role of signal transducers and activators of transcription 6-independent interleukin-4 signaling for the generation of Th2-biased pathological CD4+ betabetaT cells.

Yoshiko Okuda1, Ichiro Takahashi, Jin-Kyung Kim, Noriyuki Ohta, Kouichi Iwatani, Hideki Iijima, Yasuyuki Kai, Hiroshi Tamagawa, Takachika Hiroi, Mi-Na Kweon, Sunao Kawano, Kiyoshi Takeda, Sizuo Akira, Yutaka Sasaki, Masatsugu Hori, Hiroshi Kiyono.   

Abstract

Forbidden CD4(+)betabeta T cells, which produce interleukin (IL)-4 predominantly, are a pathological subset in the development of colitis in T-cell receptor alpha chain (TCRalpha)-deficient mice. Stimulation of naive CD4(+) T cells with IL-4 induces Th2 development via the activation of signal transducers and activators of transcription (STAT) 6. In the present study, we had found that IL-4 enhanced the expression of STAT6 in CD4(+)betabeta T cells isolated from TCRalpha(-/-) mice with colitis, suggesting that the IL-4 signal in the CD4(+)betabeta T cells is mediated by STAT6. To further investigate the role of STAT6 in the development of colitis induced by TCRalpha deficiency, we generated double-deficient mice by crossing TCRalpha(-/-) mice and STAT6(-/-) mice. Surprisingly, STAT6 deficiency did not result in decreased severity of colitis in TCRalpha(-/-) mice. STAT6-deficient CD4(+)betabeta T cells produced IL-4 and intraperitoneal injection of anti-IL-4 monoclonal antibody in the nondiseased TCRalpha(-/-) and STAT6 double-deficient mice prevented the colitis formation, thus indicating that the cells differentiated into the Th2 phenotype have the ability to mediate the development of the colitis in the absence of STAT6.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507909      PMCID: PMC1851110          DOI: 10.1016/s0002-9440(10)63817-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

1.  Stat6-dependent and -independent pathways for IL-4 production.

Authors:  M H Kaplan; A L Wurster; S T Smiley; M J Grusby
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.

Authors:  B H Ye; G Cattoretti; Q Shen; J Zhang; N Hawe; R de Waard; C Leung; M Nouri-Shirazi; A Orazi; R S Chaganti; P Rothman; A M Stall; P P Pandolfi; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-06       Impact factor: 38.330

Review 3.  STAT6: its role in interleukin 4-mediated biological functions.

Authors:  K Takeda; T Kishimoto; S Akira
Journal:  J Mol Med (Berl)       Date:  1997-05       Impact factor: 4.599

4.  CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice.

Authors:  I Takahashi; H Kiyono; S Hamada
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

5.  Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity.

Authors:  G A West; T Matsuura; A D Levine; J S Klein; C Fiocchi
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

6.  An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice.

Authors:  N Noben-Trauth; L D Shultz; F Brombacher; J F Urban; H Gu; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4.

Authors:  I C Ho; M R Hodge; J W Rooney; L H Glimcher
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

8.  Schistosoma mansoni in IL-4-deficient mice.

Authors:  E J Pearce; A Cheever; S Leonard; M Covalesky; R Fernandez-Botran; G Kohler; M Kopf
Journal:  Int Immunol       Date:  1996-04       Impact factor: 4.823

9.  Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells.

Authors:  N Corazza; S Eichenberger; H P Eugster; C Mueller
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

10.  Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease.

Authors:  A Mizoguchi; E Mizoguchi; C Chiba; G M Spiekermann; S Tonegawa; C Nagler-Anderson; A K Bhan
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

Review 2.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

3.  STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines.

Authors:  Michael J Rosen; Rupesh Chaturvedi; M Kay Washington; Lindsay A Kuhnhein; Preston D Moore; Scott S Coggeshall; Elizabeth M McDonough; Jörn-Hendrik Weitkamp; Amar B Singh; Lori A Coburn; Christopher S Williams; Fang Yan; Luc Van Kaer; R Stokes Peebles; Keith T Wilson
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

Review 4.  Effector T Helper Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Tanbeena Imam; Sungtae Park; Mark H Kaplan; Matthew R Olson
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

5.  Disturbance in the Mucosa-Associated Commensal Bacteria Is Associated with the Exacerbation of Chronic Colitis by Repeated Psychological Stress; Is That the New Target of Probiotics?

Authors:  Sohei Arase; Yohei Watanabe; Hiromi Setoyama; Noriko Nagaoka; Mitsuhisa Kawai; Satoshi Matsumoto
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.